Is CT and MRI Texture Analysis Ready For Prime Time?

Dr. Balaji Ganeshan, CEO of TexRAD and Senior Imaging Scientist at the University College of London Institute of Nuclear Medicine, will present "Quantifying Tumor Heterogeneity with TexRAD Texture Analysis on CT and MRI - Ready for Prime Time?" on Thursday, May 17th, at 12PM in the Franken Conference Room.

Texture analysis of CT, MRI, and PET images of malignancy can quantify tumor heterogeneity and provide an objective measurement which can assist in radiological and oncological practice. Heterogeneity can alter biological and physical factors including vascularity (angiogenesis), necrosis, fibrosis, proliferation, and hypoxia, all of which can be picked up via imaging features.

Dr. Ganeshan’s lecture will focus on one of the most validated and published techniques of texture analysis, known as TexRAD. Dr. Ganeshan will review TexRAD’s thorough qualification process as well as explaining:

- What does TexRAD Texture Analysis Mean?
- Biological Correlates
- Clinical Validation (Prognosis, Disease-Severity, Treatment - Response/Prediction)
- Technical Validation
- Clinical Utility and Cost-Effectiveness

Dr. Ganeshan will further give a live demonstration of the TexRAD platform including use of the TexRAD software client as well as the TexRAD data Miner.